SDLP Health Spokesperson Mark H Durkan has welcomed a Health and Social Care Board decision to approve a life extending drug for patients with pancreatic cancer.
He said: “Clinical trials have shown that Abraxane can extend the life of patients with Pancreatic cancer by up to three years.
“The decision to approve its use in Northern Ireland is a huge victory for campaigners and patients.
“Pancreatic cancer survival rates remain far too low. It’s critical that we do all we can to advance treatments and ensure that people in the North have access to those treatments.
“There can be no postcode lottery for the highest quality care,” added the Foyle MLA.
